Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.71 |
| ▸ | MAOA | P21397 | 1/20 | 0.55 |
| ▸ | HRH1 | P35367 | 4/20 | 0.49 |
| ▸ | IDO1 | P14902 | 2/20 | 0.48 |
| ▸ | AGXT | P21549 | 2/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6183551 | 0.98 | TAAR1 (0.74) | TAAR1MAOAHRH1IDO1AGXT | |
| SCHEMBL237142 | 0.92 | TAAR1 (0.77) | TAAR1MAOAIDO1AGXTSIGMAR1 | |
| Hydrochloric Acid SCHEMBL5234157 | 0.90 | TAAR1 (0.74) | TAAR1MAOAIDO1AGXTSIGMAR1 | |
| SCHEMBL19524669 | 0.90 | TAAR1 (0.65) | TAAR1IDO1AGXTSIGMAR1 | |
| SCHEMBL30957025 | 0.86 | MAOA (0.67) | TAAR1MAOAHRH1 | |
| SCHEMBL3457108 | 0.85 | TAAR1 (0.60) | TAAR1IDO1AGXTSIGMAR1 | |
| SCHEMBL3456220 | 0.85 | TAAR1 (0.60) | TAAR1IDO1AGXTSIGMAR1 | |
| SCHEMBL8731016 | 0.85 | TAAR1 (0.60) | TAAR1IDO1AGXTSIGMAR1 | |
| SCHEMBL16203114 | 0.84 | TAAR1 (0.59) | TAAR1MAOAIDO1AGXTSIGMAR1 | |
| SCHEMBL30444743 | 0.84 | TAAR1 (0.59) | TAAR1MAOAIDO1AGXTSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2499115-B1 | PROCESS FOR PREPARING HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB HOLDINGS IRELAND (CH) | 2016-07-27 | — | — | EP | disclosed |
| US-8354406-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2013-01-15 | — | — | US | disclosed |
| US-20120035164-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2012-02-09 | — | — | US | disclosed |
| US-8063071-B2 | Chemical compounds | GlaxoSmithKline, LLC (US) | 2011-11-22 | — | — | US | disclosed |
| US-20090143372-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2009-06-04 | — | — | US | disclosed |
| EP-1896014-A2 | CHEMICAL COMPOUNDS | Smithkline Beecham Corporation (US) | 2008-03-12 | — | — | EP | disclosed |
| WO-2007005534-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035164-A1 | CHEMICAL COMPOUNDS | IKBKG, NFKBIA, RELA | TAAR1 2652/4885MAOA 940/4885HRH1 296/4885 |
| US-20090143372-A1 | CHEMICAL COMPOUNDS | IKBKG, NFKBIA, RELA | TAAR1 2652/4885MAOA 940/4885HRH1 296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.